Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study)

Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) - Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034228

Enrollment

1000

Registered

2018-10-01

Start date

2018-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have more than 2 records of hospitalization between the study target period from January 2010 to February 2018. 2. Patients who have more than 2 records of hospitalization under disease name of heart failure (ICD10 code:I11.0,I50) which is considered as a reason behind hospitalization. 3. Patients who have more than 2 records of outpatient visit after the start of the follow-up period. 4. Patient who are older than 20 years at the start of the follow-up period.

Exclusion criteria

Exclusion criteria: 1.Patients whom had discharge JCS score was more than 1 at the hospitalization at the start of follow-up period. 2.Patients whom had discharge ADL score was less than 12 at the hospitalization at the start of follow-up period. 3.Patients who received pimobendan short term prescription. 4.Patients who have prescribed Vesnarinone,Denopamine,Docarpamine,during the follow-up period. 5.Patients who are prescribed inotropic injections(Dopamine hydrochloride,Dobutamine hydrochloride,PDE3inhibitors or Colforsin daropate hydrochloride) at the outpatient visits during the follow-up period. 6.Patients who had the following records within 90 days prior to the start of the follow-up period: -Cardiac surgery(CABG,Valvuloplasty,Valve replacement surgery,etc.)(category code; K522,K554,K555,K5763,K5792,Including combined operation cases.) -TAVI(category code;K555-02) -Cardiac resynchronization therapy(CRT)(category code;K598,K598-02,K599-03,K599-04) -PCI(category code;K546,K547,K548,K549,K550) 7.Patient who have the following diagnosis or procedures within the study target period:Malignant tumor(ICD10;C00-C97) -Heart transplantation(category code;K605-02) -Left Ventricular Assist Device(LVAD)(category code;C116,K603,K6042,K604-02)

Design outcomes

Primary

Measure	Time frame
The time to rehospitalization and/or the incident of readmission in heart failure patient.	—

Secondary

Measure	Time frame
Number of re-hospitalization due to heart failure Total number of hospitalizations Frequency of specific adverse event for cardiotonic drugs	—

Countries

Japan

Contacts

Public ContactMurata Tatsunori

Crecon Medical Assessment Inc. NA

tatsunori.murata@crecon.jp03-3407-4491

Outcome results